Zobrazeno 1 - 10
of 71
pro vyhledávání: '"T. Blachley"'
Autor:
W. Reiss, T. Blachley, Steve Zlotnick, Kelechi Emeanuru, Joel M. Kremer, Dimitrios A Pappas, Jennie H. Best
Publikováno v:
Rheumatology and Therapy
Introduction Understanding the durability of response to treatment and factors associated with failure to maintain response in a real-world setting can inform treatment decisions for patients with rheumatoid arthritis (RA). The aim of this study was
Autor:
Dimitrios A Pappas, Kelechi Emeanuru, T. Blachley, Susan Boklage, Jeannie Choi, Gregory St John, Rajeshwari S. Punekar, Toshio Kimura, Stefano Fiore, Carol J. Etzel, Joel M. Kremer
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThis study evaluated the comparative effectiveness of a tumour necrosis factor inhibitor (TNFi) versus a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs)) as the first-line treatm
Autor:
T. Blachley, Jennie H. Best, Steve Zlotnick, Dimitrios A. Pappas, Joel M. Kremer, Kelechi Emeanuru
Publikováno v:
Rheumatology and Therapy
Rheumatology and Therapy, Vol 7, Iss 2, Pp 357-369 (2020)
Rheumatology and Therapy, Vol 7, Iss 2, Pp 357-369 (2020)
Introduction Similar outcomes have been observed between patients with rheumatoid arthritis (RA) responding to tocilizumab (TCZ) with methotrexate (MTX) who discontinued vs. continued MTX and between patients receiving MTX who added TCZ vs. switched
Autor:
Blessing Dube, Paul R. Lakin, Alexis Ogdie, Peter Hur, T. Blachley, Philip J. Mease, Robert R. McLean
Publikováno v:
The Journal of rheumatology. 49(3)
ObjectiveTo determine the presence of axial symptoms in patients with psoriatic arthritis (PsA) and examine differences between those with or without a diagnosis of axial PsA (axPsA).MethodsPatients with PsA at their Corevitas’ (formerly Corrona) P
Autor:
P. J. Mease, T. Blachley, J. O’brien, N. Middaugh, G. Kricorian, S. Stryker, D. Collier, A. Ogdie
Publikováno v:
Annals of the Rheumatic Diseases. 81:406-407
BackgroundPsoriatic arthritis (PsA) is a burdensome, chronic disease that can impact patient functionality and quality of life. Real-world data are limited regarding the most common disease domain combinations in patients with PsA receiving biologic
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Carol J. Etzel, Jennie H. Best, Dimitrios A. Pappas, Joel M. Kremer, Steve Zlotnick, T. Blachley
Publikováno v:
Rheumatology and Therapy
Rheumatology and Therapy, Vol 6, Iss 3, Pp 421-433 (2019)
Rheumatology and Therapy, Vol 6, Iss 3, Pp 421-433 (2019)
Introduction Prednisone is frequently administered in combination with other therapies for the treatment of rheumatoid arthritis (RA); however, its chronic use is associated with an increased risk of comorbidities and mortality. The objective of this
Autor:
Susan Boklage, Toshio Kimura, Gregory St John, Jeannie Choi, Kelechi Emeanuru, Carol J Etzel, Rajeshwari Punekar, Joel M. Kremer, T. Blachley, Stefano Fiore, Dimitrios A Pappas
Publikováno v:
Annals of the rheumatic diseases. 81(11)
We thank Zheng et al 1 for their interest in our study2 and for providing constructive comments. They mention that even though the baseline mean Clinical Disease Activity Index (CDAI) was not statistically different, the proportion of patients with m
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.